Nailfold capillary density in 140 untreated children with juvenile dermatomyositis: an indicator of disease activity

[1] Mendez EP(2003)US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry Arthritis Rheum 49 300-305

[2] Lipton R(2022)Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive Sci Rep 12 275-1649

[3] Ramsey-Goldman R(2020)Serum protein biomarkers for juvenile dermatomyositis: a pilot study BMC Rheumatol 4 52-576

[4] Roettcher P(2004)Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops J Rheumatol 31 1644-347

[5] Bowyer S(2008)Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis Arthritis Rheum 58 571-436

[6] Dyer A(1975)Polymyositis and dermatomyositis (first of two parts) N Engl J Med 292 344-15

[7] Roberson EDO(2019)SDS-PAGE for 35S immunoprecipitation and immunoprecipitation western blotting Methods Mol Biol 1855 417-S157

[8] Mesa RA(2003)Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence Arthritis Rheum 49 7-55

[9] Morgan GA(2011)Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (

[10] Cao L(2019)Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients J Autoimmun 101 48-18

[1] Mendez EP(2003)US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry Arthritis Rheum 49 300-305

[2] Lipton R(2022)Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive Sci Rep 12 275-1649

[3] Ramsey-Goldman R(2020)Serum protein biomarkers for juvenile dermatomyositis: a pilot study BMC Rheumatol 4 52-576

[4] Roettcher P(2004)Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops J Rheumatol 31 1644-347

[5] Bowyer S(2008)Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis Arthritis Rheum 58 571-436

[6] Dyer A(1975)Polymyositis and dermatomyositis (first of two parts) N Engl J Med 292 344-15

[7] Roberson EDO(2019)SDS-PAGE for 35S immunoprecipitation and immunoprecipitation western blotting Methods Mol Biol 1855 417-S157

[8] Mesa RA(2003)Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence Arthritis Rheum 49 7-55

[9] Morgan GA(2011)Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (

[10] Cao L(2019)Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients J Autoimmun 101 48-18